Debbie Robbrecht

19PUBLICATIONS
118CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Apr 10, 2026
Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid Cancer.

Frits I Mulder, Noori A M Guman, Job van Riet

|Feb 27, 2026
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.

Jan-Jaap J Mellema, Chantal F Stockem, Cameron Herberts

|Nov 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.

Ignacio Melero, Josep Tabernero, Neeltje Steeghs

|Jun 01, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Mark N Stein, Armelle Vinceneux, Debbie Robbrecht

|Oct 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.

Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht

|Sep 16, 2024
Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?

Mathijs P Scholtes, Geert J L H van Leenders, Debbie G J Robbrecht

Pageof 4

Frequent Collaborators

4 joint publications

Neeltje Steeghs

3 joint publications

Martijn P Lolkema

3 joint publications

Joost L Boormans

3 joint publications

Stefan Evers